Navigation Links
ConvaTec Launches New AQUACEL(R) Ag Dressing with Strengthening Fiber
Date:5/14/2009

Now 20 Times Stronger,* Advanced Ribbon Dressing Features Hydrofiber(R) Technology

SKILLMAN, N.J., May 14 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today the launch of AQUACEL(R) Ag Dressing with Strengthening Fiber, a new advanced ribbon dressing, in the U.S. Up to 20 times stronger than the original ribbon dressing, the improved wound dressing also offers reduced shrinkage and is the only absorbent filler dressing to offer the unique gelling benefits of Hydrofiber(R) Technology plus the antimicrobial properties of ionic silver.(1,2)

The added strength of the new AQUACEL(R) Ag ribbon dressing makes it ideal for use in packing a wide variety of cavity wounds, such as post-surgical wounds, excised abscesses, pilonidal cysts, and stage III and stage IV pressure ulcers that have tunneling and undermining. In addition, AQUACEL(R) Ag dressing provides the broad-spectrum antimicrobial properties of ionic silver, which kills a broad range of pathogens in the dressing, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) as demonstrated in vitro.(3) A comparative in vitro testing of existing products showed new AQUACEL(R) Ag ribbon dressing has greater wet tensile strength -- the measure of force necessary to break the dressing when wet -- than major competitors tested.(4)

Dot Weir, RN and Program Director of The Wound Healing Center of Osceola Regional Medical Center, welcomed the launch of the new AQUACEL(R) Ag ribbon dressing in the U.S., "The new dressing provides the continued performance of excellent absorption of the wound exudate we have come to expect from Hydrofiber(R) Technology, with the added bonus of noticeable ease of removal and remarkable strength, providing pain reduction for the patient and confidence for the clinician."

T
'/>"/>

SOURCE ConvaTec
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor
2. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
3. ConvaTec Launches New Lifestyle Magazine for People With an Ostomy
4. ConvaTec Announces Expanded Indications for AQUACEL(R) and AQUACEL(R) Ag Dressings in Management of Surgical Wounds
5. ConvaTec Announces Divestiture of Unomedical Wound Care and Ophthalmics Business
6. ConvaTec Names Paul Moraviec President, Continence and Critical Care Business Unit and ConvaTec EMEA Region
7. ConvaTec and HemCon Announce Co-Promotion Agreement
8. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
9. UPMC Health Plan Launches New Personal Health Record
10. HealthInsuranceFinders.com Launches Video Contest for Young Directors
11. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... (fool) has a lip smacking meaning here. Like Ekta ... nomenclature of the restaurants// here attracts customers. ... (Big Fool)", "Sabse Bada Bewakoof" (The Biggest Fool) and ... ,"The word 'bewakoof' is the only reason for ...
... An Israeli scientist wants to turn camel milk, a healthier ... desert.,The practised method of milking normally yields// some 1.5 litres ... the yield of 20 litres produced by cows. Yagil, however, ... 15 litres per camel a day. ,Traditionally seen ...
... organize a nationwide peaceful demonstration against the reservation quota in ... proposal to hike reservation seats started on the 27th April. ... by after the assembly poll in five states was not ... 2 will be a ‘‘show of strength’’ and send the ...
... in Angola to contain the cholera outbreak there says that 20,000 ... is an acute intestinal infection, which is caused in most cases ... It’s showing even more in other provinces now also. This week ... day and in some days more than 30 deaths," said Richard ...
... journal Nature has found that Gene therapy, which is used ... cancer//. US researcher, citing an animal study say that the ... than previously thought. ,However, experts from Great Ormond ... say that gene therapy in low doses does not cause ...
... the capital of India medical students are striking against ... new step when the students said that they are ... ,They were persuading school and college students to ... to increase the Other Backward Classes (OBC) quota in ...
Cached Medicine News:Health News:Milking the ship of the desert for 'white gold' 2Health News:Nationwide Strike on May 2nd by Medicos on Reservation Issue 2Health News:'Bubble Boy' Gene Therapy Causes Cancer? 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... CVS Caremark Corporation (NYSE: CVS ), today announced ... ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... Net revenues increased 12.5% to a record $26.7 billion ... Retail Pharmacy segment revenues increased 3.8%, with same ...
... Bellicum Pharmaceuticals, Inc. today announced publication in ... results using a new therapy that demonstrated rapid and ... Inducible Apoptosis as a Safety Switch for Adoptive Cell ... ™ technology to eliminate donor T cells causing ...
Cached Medicine Technology:CVS Caremark Reports Third Quarter Results 2CVS Caremark Reports Third Quarter Results 3CVS Caremark Reports Third Quarter Results 4CVS Caremark Reports Third Quarter Results 5CVS Caremark Reports Third Quarter Results 6CVS Caremark Reports Third Quarter Results 7CVS Caremark Reports Third Quarter Results 8CVS Caremark Reports Third Quarter Results 9CVS Caremark Reports Third Quarter Results 10CVS Caremark Reports Third Quarter Results 11CVS Caremark Reports Third Quarter Results 12CVS Caremark Reports Third Quarter Results 13CVS Caremark Reports Third Quarter Results 14CVS Caremark Reports Third Quarter Results 15Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 2Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 3Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: